Claro Advisors LLC Has $1.28 Million Stake in Stryker Co. (NYSE:SYK)

Claro Advisors LLC decreased its holdings in Stryker Co. (NYSE:SYK) by 10.1% in the 4th quarter, Holdings Channel.com reports. The firm owned 3,542 shares of the medical technology company’s stock after selling 399 shares during the period. Claro Advisors LLC’s holdings in Stryker were worth $1,275,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also bought and sold shares of the business. Dunhill Financial LLC raised its position in shares of Stryker by 94.9% in the 3rd quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock valued at $27,000 after buying an additional 37 shares in the last quarter. Centennial Bank AR increased its position in Stryker by 106.7% during the 2nd quarter. Centennial Bank AR now owns 93 shares of the medical technology company’s stock worth $32,000 after purchasing an additional 48 shares in the last quarter. Darwin Wealth Management LLC bought a new stake in Stryker during the 3rd quarter worth approximately $36,000. Hara Capital LLC bought a new stake in shares of Stryker in the 3rd quarter valued at $42,000. Finally, HBW Advisory Services LLC bought a new stake in shares of Stryker in the 3rd quarter valued at $42,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Insider Transactions at Stryker

In related news, CEO Kevin Lobo sold 57,313 shares of the company’s stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $368.70, for a total value of $21,131,303.10. Following the sale, the chief executive officer now owns 100,027 shares in the company, valued at $36,879,954.90. This represents a 36.43 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 5.90% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on SYK shares. JPMorgan Chase & Co. upped their price objective on shares of Stryker from $375.00 to $420.00 and gave the stock an “overweight” rating in a report on Wednesday, October 30th. Piper Sandler reiterated an “overweight” rating and set a $420.00 target price (up previously from $380.00) on shares of Stryker in a research report on Wednesday, October 30th. BTIG Research raised their target price on shares of Stryker from $383.00 to $394.00 and gave the company a “buy” rating in a research note on Wednesday, October 30th. Royal Bank of Canada restated an “outperform” rating and issued a $425.00 target price on shares of Stryker in a report on Tuesday, January 7th. Finally, Citigroup lifted their price target on shares of Stryker from $411.00 to $450.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. Four equities research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $405.80.

Stryker Trading Down 1.2 %

SYK stock traded down $4.39 during midday trading on Monday, reaching $361.27. The company’s stock had a trading volume of 870,932 shares, compared to its average volume of 1,215,035. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.22 and a current ratio of 1.91. The stock has a fifty day simple moving average of $375.40 and a two-hundred day simple moving average of $357.95. Stryker Co. has a 1 year low of $307.23 and a 1 year high of $398.20. The firm has a market capitalization of $137.72 billion, a price-to-earnings ratio of 38.72, a PEG ratio of 2.82 and a beta of 0.95.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.77 by $0.10. The business had revenue of $5.49 billion for the quarter, compared to the consensus estimate of $5.37 billion. Stryker had a return on equity of 23.07% and a net margin of 16.34%. The business’s revenue was up 11.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.46 EPS. On average, equities research analysts predict that Stryker Co. will post 12.06 EPS for the current year.

Stryker Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st will be paid a dividend of $0.84 per share. This is a positive change from Stryker’s previous quarterly dividend of $0.80. The ex-dividend date of this dividend is Tuesday, December 31st. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.93%. Stryker’s payout ratio is presently 36.01%.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.